Therapeutics News and Research

RSS

Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Researchers at the Gladstone Institutes have shown that reducing brain levels of the protein tau effectively blocks the development of disease in a mouse model of Dravet syndrome, a severe intractable form of childhood epilepsy.

14 Aug 2014

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

13 Aug 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014.

12 Aug 2014

New approach to knocking out parasite's genes

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics.

12 Aug 2014

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Halozyme Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2014. Financial highlights for the second quarter include revenues of $18.4 million and a net loss of $16.3 million, or $0.13 per share.

12 Aug 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013.

11 Aug 2014

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

New research partly led by UC San Francisco-affiliated scientists suggests that one in 10 cancer patients would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments.

8 Aug 2014

Notch signaling also plays important role in onset of obesity and Type 2 diabetes

A Purdue University study shows that Notch signaling, a key biological pathway tied to development and cell communication, also plays an important role in the onset of obesity and Type 2 diabetes, a discovery that offers new targets for treatment.

8 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014.

7 Aug 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014.

7 Aug 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Researchers take major step forward in developing real ALS treatments

A series of studies begun by Harvard Stem Cell Institute scientists eight years ago has lead to a report published today that may be a major step forward in the quest to develop real treatments for amyotrophic lateral sclerosis, ALS, or Lou Gehrig's disease.

7 Aug 2014

Altering the circadian rhythm: an interview with Dr. Doug Kojetin, The Scripps Research Institute

The circadian rhythm is affected by many different stimuli—such as sleep and light, which are the most broadly appreciated ways—but also eating— all of which can modulate, or change, important processes in our bodies such as temperature, production of hormones or other signalling small molecules, cellular regeneration, and others.

6 Aug 2014

Oraya awarded NIH grant to study how gold nanoparticles can enhance Wet AMD treatment

Oraya Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD).

6 Aug 2014

Kids are at risk of biological damage results from microwave radiation emitted by wireless devices

A scholarly article on wireless safety, published online in the Journal of Microscopy and Ultrastructure, reports that children and fetuses are the most at risk from neurological and biological damage that results from microwave radiation emitted by wireless devices, due to the higher rate of absorption of microwave radiation by children than by adults.

6 Aug 2014

Therapeutics News and Research

Reducing brain levels of tau protein effectively blocks development of childhood epilepsy

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Omeros reports net loss of $18 million for second quarter 2014

New approach to knocking out parasite's genes

Halozyme reports revenues of $18.4 million, net loss of $16.3 million for Q2 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Scientists analyze genetic characteristics of cancers using multiple genomic technology platforms

Notch signaling also plays important role in onset of obesity and Type 2 diabetes

Idera collaborates with TMA to advance new potential treatment approach for myositis

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Celsion announces financial results for second quarter ended 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Researchers take major step forward in developing real ALS treatments

Altering the circadian rhythm: an interview with Dr. Doug Kojetin, The Scripps Research Institute

Oraya awarded NIH grant to study how gold nanoparticles can enhance Wet AMD treatment

Kids are at risk of biological damage results from microwave radiation emitted by wireless devices

Aeterna Zentaris signs strategic co-promotion services agreement with ASCEND

Research roundup: The effect of expensive cancer therapies; missed hospital handovers; children's mental health needs

New versatile method for making artificial anti-cancer molecules in minutes

Artesunate drug can be used to control asthma, finds NUS study

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News